Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds


Press Release

Sight Diagnostics Ltd. and the United States Army Announce a Joint Collaboration

Sight Diagnostics
Posted on: 26 Oct 16

TEL AVIV, Israel, October 25, 2016 /PRNewswire/ --

Sight Diagnostics (SightDx) today announced a collaboration with the United States Army Medical Research Directorate Kenya (USAMRD-K) to develop and test the next generation of the SightDx malaria diagnostic technology. Sight Diagnostics will be developing and producing a portable malaria and complete blood count (CBC) reader that will be calibrated and tested in clinical trials at the USAMRD-K Field Station in Kisumu, Kenya.  

Mr. Yossi Pollak, CEO of SightDx said, "We are very excited about the partnership with USAMRD-K. This award recognizes SightDx's success in bringing a high-throughput computer vision malaria diagnostic technology to the market and sets us on a path to launch a point of care version of the platform in remote locations and austere environments. USAMRD-K in Kisumu, Kenya serves as an ideal partner, given their extensive background in malaria clinical research and expertise in malaria diagnostics."

SightDx currently markets the Parasight device, a high-throughput malaria detection platform that uses computer vision technology to analyze blood samples for malaria parasites. The state-of-the-art digital cytometry technology combines cutting-edge computer vision algorithms, custom optics, and proprietary disposable cartridges, which allows for analyzing blood samples in a rapid, reliable and a completely automated fashion. The platform has shown ~98% sensitivity and ~98% specificity in clinical trials performed in Africa and India. The device is currently marketed throughout Europe, Africa and India with over 60 units having been placed in pathology laboratories and hospitals.

SightDx aims to develop and test a portable version of the malaria diagnostic technology which will also perform complete blood count, providing additional diagnostic information critical to health care providers operating in remote locations. In contrast to the current device that can hold 30 tests and features automated loading and scanning, the next generation device will scan a single cartridge of five tests and have significantly smaller dimensions, making it appropriate for smaller clinics in rural areas.  

The project will be conducted in collaboration with Dr. John Waitumbi, senior scientist and chief of the Basic Science Laboratory at USAMRD-K, which is part of the Walter Reed Army Institute of Research (WRAIR). The USAMRD-K mission includes conducting regulated clinical trials for vaccines, drugs and diagnostic platforms for diseases of Africa and the world. In addition, USAMRD-K conducts surveillance, training, research and response activities related to emerging infectious disease threats as well being a partner in executing the U.S. President's Emergency Plan for AIDS Relief (PEPFAR) and the President's Malaria Initiative (PMI).

"Malaria microscopy and rapid diagnostic tests (RDTs) have been the mainstay of malaria diagnosis for centuries and decades, respectively. If proven successful, the instrument from SightDx will help detect and quantify malaria parasites.  It will also provide the patient's blood count (anemic status), an important parameter in the management of patients diagnosed with malaria," said Waitumbi. "This collaboration recognizes the expertise and capability of USAMRD-K to evaluate the performance of potential diagnostic devices for diseases that are endemic to Kenya and the region."

In 2015, there were 214 million new cases of malaria worldwide resulting in 438,000 malaria deaths. The WHO estimates that nearly 500 million malaria tests are performed annually to combat the disease. While microscopy and RDTs are the main diagnostic approaches, there is recognition of the need to take improved diagnostics to the "point of need." Such devices need to be inexpensive, quick, consistent and highly accurate. The development and launch of the point-of-care device for malaria diagnosis, featuring complete blood count, will allow for wider use of the platform to enable better patient management.

About WRAIR 

Headquartered in Silver Spring, Maryland and established in 1893, the Walter Reed Army Institute of Research (WRAIR) is the oldest, largest and most programmatically diverse military research institute of the US Army Medical Research and Material Command and the US Department of Defense. With four overseas research units in Kenya, Thailand, Germany, and the Caucasus region, WRAIR is comprised of two Centers of Excellence, the Center for Infectious Disease Research and the Center for Military Psychiatry and Neuroscience for the purpose of benefiting both soldier health and global health. For more information, visit

About Sight Diagnostics 

Sight Diagnostics has developed a groundbreaking platform for blood analysis and infectious disease diagnostics based on its innovations in Computer Vision technology. Sight Diagnostics' platform builds on breakthroughs in sample preparation, biological staining, machine-vision algorithms, and clinical instrumentation, to provide a complete diagnostic solution that is suitable for point-of-care use. Sight Diagnostics' first product, the Parasight Malaria Detection Platform, is the first commercial malaria reader that identifies, enumerates, and speciates malarial parasites with high accuracy. In the future, the technology will detect additional pathogens and blood anomalies. For more information, please visit

For more information, please contact:
Josh Turner
Media Relations
Mobile: +1-917-231-0550

For more information:

Editor's Details

Mike Wood

Last updated on: 26/10/2016

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.